Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply exposed individuals to HIV-1 infection

Author(s): Liu R, Paxton WA, Choe S, Ceradini D, Martin SR et al.

Abstract

Rare individuals have been multiply exposed to HIV-1 but remain uninfected. The CD4+ T-cells of two of these individuals, designated EU2 and EU3, are highly resistant in vitro to the entry of primary macrophage-tropic virus but are readily infectable with transformed T-cell line adapted viruses. We report here on the genetic basis of this resistance. We found that EU2 and EU3 have a homozygous defect in CKR-5, the gene encoding the recently described coreceptor for primary HIV-1 isolates. These individuals appear to have inherited a defective CKR-5 allele that contains an internal 32 base pair deletion. The encoded protein is severely truncated and cannot be detected at the cell surface. Surprisingly, this defect has no obvious phenotype in the affected individuals. Thus, a CKR-5 allele present in the human population appears to protect homozygous individuals from sexual transmission of HIV-1. Heterozygous individuals are quite common (∼20%) in some populations. These findings indicate the importance of CKR-5 in HIV-1 transmission and suggest that targeting the HIV-1–CKR-5 interaction may provide a means of preventing or slowing disease progression.

Similar Articles

Trial, error and breakthrough: A review of HIV vaccine development

Author(s): Barry SM, Mena Lora AJ, Novak RM

Cell responses to HIV-1 infection and vaccination: pathways to preventing infection

Author(s): Haynes BF, Moody MA, Liao HX, Verkoczy L, Tomaras GD

The antigenic structure of the HIV gp120 envelope glycoprotein

Author(s): Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, et al.

Crystal structure of a soluble cleaved HIV-1 envelope trimer

Author(s): Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, et al.

Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer

Author(s): Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, et al.

Gene therapy as a vaccine for HIV-1

Author(s): Berkhout B, Sanders RW

Antibody gene transfer for HIV immunoprophylaxis

Author(s): Balazs AB, West AP

Rapamycin-regulated control of antiangiogenic tumor therapy following raav-mediated gene transfer

Author(s): Nguyen M, Huan-Tu G, Gonzalez-Edick M, Rivera VM, Clackson T, et al.

Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation

Author(s): Hütter G, Nowak D, Mossner M, Ganepola S, Müßig A, et al.

Novel targets for antiretroviral therapy

Author(s): Dau B, Holodniy M.

Study record detail USA

Author(s): US National library of Medicine

Study record detail USA

Author(s): US National library of Medicine

Study record detail USA

Author(s): US National library of Medicine

Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env

Author(s): Scharf L, Wang H, Gao H, Chen S, McDowall AW, et al.